Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

H. Zuo; P. M. Ueland; Midttun; G. S. Tell; A. Fanidi; W. Zheng; X. Shu; Y. Xiang; J. Wu; R. Prentice; M. Pettinger; C. A. Thomson; G. G. Giles; A. Hodge; Q. Cai; W. J. Blot; M. Johansson; J. Hultdin; K. Grankvist; V. L. Stevens; M. L. McCullough; S. J. Weinstein; D. Albanes; R. G. Ziegler; N. D. Freedman; N. E. Caporaso; A. Langhammer; K. Hveem; M. Næss; J. E. Buring; I. Lee; J. M. Gaziano; G. Severi; X. Zhang; M. J. Stampfer; J. Han; A. Zeleniuch-Jacquotte; L. L. Marchand; J. Yuan; R. Wang; W. Koh; Y. Gao; U. Ericson; K. Visvanathan; M. R. Jones; C. Relton; P. Brennan; M. Johansson; A. Ulvik

doi:10.1093/annonc/mdz002

Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

H. Zuo^*, P. M. Ueland, Midttun, G. S. Tell, A. Fanidi, W. Zheng, X. Shu, Y. Xiang, J. Wu, R. Prentice, M. Pettinger, C. A. Thomson, G. G. Giles, A. Hodge, Q. Cai, W. J. Blot, M. Johansson, J. Hultdin, K. Grankvist, V. L. StevensM. L. McCullough, S. J. Weinstein, D. Albanes, R. G. Ziegler, N. D. Freedman, N. E. Caporaso, A. Langhammer, K. Hveem, M. Næss, J. E. Buring, I. Lee, J. M. Gaziano, G. Severi, X. Zhang, M. J. Stampfer, J. Han, A. Zeleniuch-Jacquotte, L. L. Marchand, J. Yuan, R. Wang, W. Koh, Y. Gao, U. Ericson, K. Visvanathan, M. R. Jones, C. Relton, P. Brennan, M. Johansson, A. Ulvik

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

20 Citations (Scopus)

163 Downloads (Pure)

Abstract

Background: Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal -5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known.

Materials and methods: For this study, we included 5,323 incident lung cancer cases and 5,323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models.

Results: PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36- 2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23).

Conclusion: Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

Original language	English
Article number	mdz002
Pages (from-to)	478-485
Number of pages	8
Journal	Annals of Oncology
Volume	30
Issue number	3
Early online date	30 Jan 2019
DOIs	https://doi.org/10.1093/annonc/mdz002
Publication status	Published - 30 Jan 2019

Bibliographical note

Keywords

PAr
nested case-control study
inflammation
Lung Cancer Cohort Consortium
lung cancer
vitamin B6

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz002

Full-text PDF (author accepted manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdz002/5304407 . Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 291 KB
Supplementary MaterialsAccepted author manuscript, 258 KB
Figure 1Accepted author manuscript, 190 KB
Figure 2Accepted author manuscript, 70.7 KB
Figure 3Accepted author manuscript, 800 KB
Figure 4Accepted author manuscript, 441 KB
Table 1Accepted author manuscript, 20.8 KB

Handle.net

Persistent link

Cite this

Zuo, H., Ueland, P. M., Midttun, Tell, G. S., Fanidi, A., Zheng, W., Shu, X., Xiang, Y., Wu, J., Prentice, R., Pettinger, M., Thomson, C. A., Giles, G. G., Hodge, A., Cai, Q., Blot, W. J., Johansson, M., Hultdin, J., Grankvist, K., ... Ulvik, A. (2019). Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3). Annals of Oncology, 30(3), 478-485. Article mdz002. https://doi.org/10.1093/annonc/mdz002

@article{e35b7395c6844153b6c9d11d4d674fd1,

title = "Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)",

abstract = "Background: Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal -5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods: For this study, we included 5,323 incident lung cancer cases and 5,323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95\% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results: PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95\% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95\% CI: 1.36- 2.10), men (OR: 1.60, 95\% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95\% CI: 1.34-2.23). Conclusion: Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.",

keywords = "PAr, nested case-control study, inflammation, Lung Cancer Cohort Consortium, lung cancer, vitamin B6",

author = "H. Zuo and Ueland, \{P. M.\} and Midttun and Tell, \{G. S.\} and A. Fanidi and W. Zheng and X. Shu and Y. Xiang and J. Wu and R. Prentice and M. Pettinger and Thomson, \{C. A.\} and Giles, \{G. G.\} and A. Hodge and Q. Cai and Blot, \{W. J.\} and M. Johansson and J. Hultdin and K. Grankvist and Stevens, \{V. L.\} and McCullough, \{M. L.\} and Weinstein, \{S. J.\} and D. Albanes and Ziegler, \{R. G.\} and Freedman, \{N. D.\} and Caporaso, \{N. E.\} and A. Langhammer and K. Hveem and M. N{\ae}ss and Buring, \{J. E.\} and I. Lee and Gaziano, \{J. M.\} and G. Severi and X. Zhang and Stampfer, \{M. J.\} and J. Han and A. Zeleniuch-Jacquotte and Marchand, \{L. L.\} and J. Yuan and R. Wang and W. Koh and Y. Gao and U. Ericson and K. Visvanathan and Jones, \{M. R.\} and C. Relton and P. Brennan and M. Johansson and A. Ulvik",

note = "{\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].",

year = "2019",

month = jan,

day = "30",

doi = "10.1093/annonc/mdz002",

language = "English",

volume = "30",

pages = "478--485",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "3",

}

Zuo, H, Ueland, PM, Midttun, Tell, GS, Fanidi, A, Zheng, W, Shu, X, Xiang, Y, Wu, J, Prentice, R, Pettinger, M, Thomson, CA, Giles, GG, Hodge, A, Cai, Q, Blot, WJ, Johansson, M, Hultdin, J, Grankvist, K, Stevens, VL, McCullough, ML, Weinstein, SJ, Albanes, D, Ziegler, RG, Freedman, ND, Caporaso, NE, Langhammer, A, Hveem, K, Næss, M, Buring, JE, Lee, I, Gaziano, JM, Severi, G, Zhang, X, Stampfer, MJ, Han, J, Zeleniuch-Jacquotte, A, Marchand, LL, Yuan, J, Wang, R, Koh, W, Gao, Y, Ericson, U, Visvanathan, K, Jones, MR, Relton, C, Brennan, P, Johansson, M & Ulvik, A 2019, 'Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)', Annals of Oncology, vol. 30, no. 3, mdz002, pp. 478-485. https://doi.org/10.1093/annonc/mdz002

TY - JOUR

T1 - Vitamin B6 catabolism and lung cancer risk

T2 - Results from the Lung Cancer Cohort Consortium (LC3)

AU - Zuo, H.

AU - Ueland, P. M.

AU - Midttun, null

AU - Tell, G. S.

AU - Fanidi, A.

AU - Zheng, W.

AU - Shu, X.

AU - Xiang, Y.

AU - Wu, J.

AU - Prentice, R.

AU - Pettinger, M.

AU - Thomson, C. A.

AU - Giles, G. G.

AU - Hodge, A.

AU - Cai, Q.

AU - Blot, W. J.

AU - Johansson, M.

AU - Hultdin, J.

AU - Grankvist, K.

AU - Stevens, V. L.

AU - McCullough, M. L.

AU - Weinstein, S. J.

AU - Albanes, D.

AU - Ziegler, R. G.

AU - Freedman, N. D.

AU - Caporaso, N. E.

AU - Langhammer, A.

AU - Hveem, K.

AU - Næss, M.

AU - Buring, J. E.

AU - Lee, I.

AU - Gaziano, J. M.

AU - Severi, G.

AU - Zhang, X.

AU - Stampfer, M. J.

AU - Han, J.

AU - Zeleniuch-Jacquotte, A.

AU - Marchand, L. L.

AU - Yuan, J.

AU - Wang, R.

AU - Koh, W.

AU - Gao, Y.

AU - Ericson, U.

AU - Visvanathan, K.

AU - Jones, M. R.

AU - Relton, C.

AU - Brennan, P.

AU - Johansson, M.

AU - Ulvik, A.

PY - 2019/1/30

Y1 - 2019/1/30

N2 - Background: Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal -5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods: For this study, we included 5,323 incident lung cancer cases and 5,323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results: PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36- 2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion: Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

AB - Background: Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal -5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods: For this study, we included 5,323 incident lung cancer cases and 5,323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results: PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36- 2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion: Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

KW - PAr

KW - nested case-control study

KW - inflammation

KW - Lung Cancer Cohort Consortium

KW - lung cancer

KW - vitamin B6

UR - https://www.scopus.com/pages/publications/85064129265

U2 - 10.1093/annonc/mdz002

DO - 10.1093/annonc/mdz002

M3 - Article (Academic Journal)

C2 - 30698666

AN - SCOPUS:85064129265

SN - 0923-7534

VL - 30

SP - 478

EP - 485

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

M1 - mdz002

ER -

Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this